BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25111790)

  • 1. Inhibin alpha-subunit (INHA) expression in adrenocortical cancer is linked to genetic and epigenetic INHA promoter variation.
    Hofland J; Steenbergen J; Voorsluijs JM; Verbiest MM; de Krijger RR; Hofland LJ; de Herder WW; Uitterlinden AG; Feelders RA; de Jong FH
    PLoS One; 2014; 9(8):e104944. PubMed ID: 25111790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum inhibin pro-αC is a tumor marker for adrenocortical carcinomas.
    Hofland J; Feelders RA; van der Wal R; Kerstens MN; Haak HR; de Herder WW; de Jong FH
    Eur J Endocrinol; 2012 Feb; 166(2):281-9. PubMed ID: 22127493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Wnt and TGF-β pathway components and key adrenal transcription factors in adrenocortical tumors: association to carcinoma aggressiveness.
    Parviainen H; Schrade A; Kiiveri S; Prunskaite-Hyyryläinen R; Haglund C; Vainio S; Wilson DB; Arola J; Heikinheimo M
    Pathol Res Pract; 2013 Aug; 209(8):503-9. PubMed ID: 23866946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic regulation of inhibin alpha-subunit gene in prostate cancer cell lines.
    Balanathan P; Ball EM; Wang H; Harris SE; Shelling AN; Risbridger GP
    J Mol Endocrinol; 2004 Feb; 32(1):55-67. PubMed ID: 14765992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
    Korah R; Healy JM; Kunstman JW; Fonseca AL; Ameri AH; Prasad ML; Carling T
    Mol Cancer; 2013 Aug; 12():87. PubMed ID: 23915220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas.
    Creemers SG; van Koetsveld PM; van Kemenade FJ; Papathomas TG; Franssen GJ; Dogan F; Eekhoff EM; van der Valk P; de Herder WW; Janssen JA; Feelders RA; Hofland LJ
    Endocr Relat Cancer; 2016 Sep; 23(9):727-37. PubMed ID: 27535174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
    Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
    Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors.
    Fonseca AL; Kugelberg J; Starker LF; Scholl U; Choi M; Hellman P; Åkerström G; Westin G; Lifton RP; Björklund P; Carling T
    Genes Chromosomes Cancer; 2012 Oct; 51(10):949-60. PubMed ID: 22733721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of inhibin alpha in adrenocortical tumours reflects the hormonal status of the neoplasm.
    Arola J; Liu J; Heikkilä P; Ilvesmäki V; Salmenkivi K; Voutilainen R; Kahri AI
    J Endocrinol; 2000 May; 165(2):223-9. PubMed ID: 10810286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Origin and identity of adrenocortical tumors in inhibin knockout mice: implications for cellular plasticity in the adrenal cortex.
    Looyenga BD; Hammer GD
    Mol Endocrinol; 2006 Nov; 20(11):2848-63. PubMed ID: 16873442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the gene for the alpha-subunit of inhibin in human adrenocortical tumours.
    Rich N; Gaston V; Le Bouc Y; Gicquel C
    Horm Res; 2002; 57(1-2):43-7. PubMed ID: 12006719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors.
    De Martino MC; Feelders RA; de Herder WW; van Koetsveld PM; Dogan F; Janssen JA; Waaijers AM; Pivonello C; Lamberts SW; Colao A; de Krijger RR; Pivonello R; Hofland LJ
    Endocr Relat Cancer; 2014 Aug; 21(4):601-13. PubMed ID: 24891456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms.
    Hofland J; Timmerman MA; de Herder WW; van Schaik RH; de Krijger RR; de Jong FH
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):792-9. PubMed ID: 17121532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
    Svahn F; Paulsson JO; Stenman A; Fotouhi O; Mu N; Murtha TD; Korah R; Carling T; Bäckdahl M; Wang N; Juhlin CC; Larsson C
    Int J Mol Med; 2018 Sep; 42(3):1675-1683. PubMed ID: 29956721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibin alpha-subunit (INHA) gene and locus changes in paediatric adrenocortical tumours from TP53 R337H mutation heterozygote carriers.
    Longui CA; Lemos-Marini SH; Figueiredo B; Mendonca BB; Castro M; Liberatore R; Watanabe C; Lancellotti CL; Rocha MN; Melo MB; Monte O; Calliari LE; Guerra-Junior G; Baptista MT; Sbragia-Neto L; Latronico AC; Moreira A; Tardelli AM; Nigri A; Taymans SE; Stratakis CA
    J Med Genet; 2004 May; 41(5):354-9. PubMed ID: 15121773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomerase and N-Cadherin Differential Importance in Adrenocortical Cancers and Adenomas.
    Pereira SS; Máximo V; Coelho R; Batista R; Soares P; Guerreiro SG; Sobrinho-Simões M; Monteiro MP; Pignatelli D
    J Cell Biochem; 2017 Aug; 118(8):2064-2071. PubMed ID: 27886397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of an m6A RNA Methylation Regulators-Based Signature for Predicting the Prognosis of Adrenocortical Carcinoma.
    Shen C; Liu J; Yang X; Jiao W; Wang Y
    Front Endocrinol (Lausanne); 2021; 12():568397. PubMed ID: 33692753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
    Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
    Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
    Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
    BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
    Creemers SG; van Koetsveld PM; van den Dungen ES; Korpershoek E; van Kemenade FJ; Franssen GJ; de Herder WW; Feelders RA; Hofland LJ
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4574-4584. PubMed ID: 27603910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.